Welcome to Francis Academic Press

International Journal of Frontiers in Medicine, 2023, 5(9); doi: 10.25236/IJFM.2023.050904.

Current progress of stem cell-based therapy


Zonglin Li, Songhao Zuo, Jinyuan Xing, Hanzhong Zhang, Liuziwen Chen, Zihao Zhao

Corresponding Author:
Zonglin Li

Beijing 21st Century International School, Beijing, China


Stem cell therapy is a promising treatment for several diseases. In this review, we summarized various cell treatments for some specific diseases, such as cell replacement therapies for Parkinsons disease. We discussed the issues and advantages of fetal neural stem cells, embryonic stem cell- and induced pluripotent stem cell-derived dopaminergic progenitors. We also described the advances and challenges for mesenchymal stem cell treatment for pulmonary fibrosis. Finally, we analyzed the potential mechanism and characteristics of stem cell therapy, and put forward prospects for the application of stem cells.


stem cell therapy, neurodegeneration disease, neuroregeneration, pulmonary fibrosis

Cite This Paper

Zonglin Li, Songhao Zuo, Jinyuan Xing, Hanzhong Zhang, Liuziwen Chen, Zihao Zhao. Current progress of stem cell-based therapy. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 9: 19-23. https://doi.org/10.25236/IJFM.2023.050904.


[1] Stoddard-Bennett T, Pera RR: Stem cell therapy for Parkinson's disease: safety and modeling.Neural Regen Res 2020, 15(1):36-40.

[2] Guo X, Tang L, Tang X: Current Developments in Cell Replacement Therapy for Parkinson's Disease. Neuroscience 2021, 463:370-382.

[3] Xiong M, Tao Y, Gao Q, Feng B, Yan W, Zhou Y, Kotsonis TA, Yuan T, You Z, Wu Z et al: Human Stem Cell-Derived Neurons Repair Circuits and Restore Neural Function. Cell Stem Cell 2021, 28(1):112-126 e116.

[4] Han F, Hu B: Stem Cell Therapy for Parkinson's Disease. Adv Exp Med Biol 2020, 1266:21-38.

[5] Sonntag KC, Simunovic F, Sanchez-Pernaute R: Stem cells and cell replacement therapy for Parkinson's disease. J Neural Transm Suppl 2009(73):287-299.

[6] Pera MF, Reubinoff B, Trounson A: Human embryonic stem cells. Journal of Cell Science 2000, 113(1):5-10.

[7] Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM: Embryonic Stem Cell Lines Derived from Human Blastocysts. Science 1998, 282(5391):880-881.

[8] Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, Armstrong L, Djonov V, Lako M, Stojkovic M: Ethical and Safety Issues of Stem Cell-Based Therapy. International journal of medical sciences 2018, 15(1):36-45.

[9] Liu Z, Cheung HH: Stem Cell-Based Therapies for Parkinson Disease. Int J Mol Sci 2020, 21(21).

[10] Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126(4):663-676.

[11] Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ: Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451(7175):141-146.

[12] Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R et al: Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318(5858):1917-1920.

[13] Sonntag KC, Song B, Lee N, Jung JH, Cha Y, Leblanc P, Neff C, Kong SW, Carter BS, Schweitzer J et al: Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects. Prog Neurobiol 2018, 168:1-20.

[14] Kikuchi T, Morizane A, Doi D, Magotani H, Onoe H, Hayashi T, Mizuma H, Takara S, Takahashi R, Inoue H et al: Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model. Nature 2017, 548(7669):592-596.

[15] Song B, Cha Y, Ko S, Jeon J, Lee N, Seo H, Park KJ, Lee IH, Lopes C, Feitosa M et al: Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models. J Clin Invest 2020, 130(2):904-920.

[16] Hiller BM, Marmion DJ, Thompson CA, Elliott NA, Federoff H, Brundin P, Mattis VB, McMahon CW, Kordower JH: Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinson's disease. NPJ Regen Med 2022, 7(1):24.

[17] Doi D, Magotani H, Kikuchi T, Ikeda M, Hiramatsu S, Yoshida K, Amano N, Nomura M, Umekage M, Morizane A et al: Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease. Nat Commun 2020, 11(1):3369.

[18] Takahashi J: iPS cell-based therapy for Parkinson's disease: A Kyoto trial. Regen Ther 2020, 13:18-22.

[19] Li DY, Li RF, Sun DX, Pu DD, Zhang YH: Mesenchymal stem cell therapy in pulmonary fibrosis: a meta-analysis of preclinical studies. Stem Cell Res Ther 2021, 12(1):461.

[20] Li S, Zhang J, Feng G, Jiang L, Chen Z, Xin W, Zhang X: The Emerging Role of Extracellular Vesicles from Mesenchymal Stem Cells and Macrophages in Pulmonary Fibrosis: Insights into miRNA Delivery. Pharmaceuticals (Basel) 2022, 15(10).

[21] Dinh PC, Paudel D, Brochu H, Popowski KD, Gracieux MC, Cores J, Huang K, Hensley MT, Harrell E, Vandergriff AC et al: Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis. Nat Commun 2020, 11(1):1064.